Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients.

Tongtong WangYingchu LiuChunyu ZhuSiyuan YangDi YangJiang XiaoGuiju Gao

Published in: Infection and drug resistance (2023)

Our study shows that the use of rifampicin in HIV/TB co-infection patients does not affect efavirenz drug concentrations, that virological suppression is good and that no efavirenz dose adjustment is required.

Keyphrases

antiretroviral therapy
hiv infected
end stage renal disease
mycobacterium tuberculosis
ejection fraction
newly diagnosed
chronic kidney disease
hiv infected patients
hepatitis c virus
peritoneal dialysis
patient reported outcomes